Login
Companies $PEPG
$4.19 +$0.00 (0.0%) After hours
PepGen Inc. logo

PepGen Inc.

pepgen.com

What Do They Do?

Develops peptide-delivered oligonucleotide therapies for people with severe neuromuscular and neurologic diseases, with current development focused on a treatment for myotonic dystrophy.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −8% (Loss)
vs −$18M in Q3 FY2025

Portfolio focus The older report centered the pipeline on a Duchenne muscular dystrophy candidate and listed further Duchenne programs. The latest report centers development on a myotonic dystrophy candidate and says Duchenne research and development is being wound down.

Who Do They Compete With?

Competes with Avidity Biosciences, Dyne Therapeutics, Entrada Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Sarepta Therapeutics, ARTHEx Biotech, AMO Pharma, Sanofi, Astellas, Modalis, Kate Therapeutics, Arrakis Therapeutics, Rgenta Therapeutics, Alnylam Pharmaceuticals, Aro Biotherapeutics, Ionis Pharmaceuticals, and PYC Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support